Cancer Patient Populations

The Johns Hopkins Medical Institutions, located in Baltimore, serve the medical needs of a multi-racial population including many individuals from the immediate neighborhood and from a tri-state region. The clinical patient care and service resources available at Johns Hopkins will be well integrated with the research activities of the SPORE. Patients will be recruited from the Johns Hopkins Colposcopy Service, the Kelly Gynecologic Oncology Service, and from referring physicians. Annually, the Colposcopy Service treats over 800 patients, approximately 15% of whom have high-grade lesions, about 2/3 of which are CIN3. Of these, approximately 60% of CIN3 cases are caused by HPV16. Roughly, 1/3 of these cases are in women who are African American. This SPORE will also recruit patients for trials from other hospital centers including the Johns Hopkins Bayview Medical Center and the Johns Hopkins Outpatient Center at Greenspring (a satellite clinic). It is recognized that optimal accrual to this study may require a larger referral population than that within the Johns Hopkins institutions. Thus, in order to increase our patient recruitment for our proposed clinical trials, we have established collaboration with two gynecologic oncologists, Drs. Warner Huh and Trey Leath, whom are both at the Department of Obstetrics and Gynecology at UAB. The infrastructure of the Division of Gynecologic Oncology at UAB and the significant cervical cancer patient population at UAB represent an essential component to our SPORE Program. Cervical neoplasia has been a research priority for over four decades at the UAB. Alabama has one of the highest incidence rates of cervical cancer in the United States: Alabama incidence rate 8.6/100,000 vs. U.S. incidence rate 7.6/100,000) (American Cancer Society, 2017). Approximately 200 women per year are diagnosed with invasive cervical cancer in the state of Alabama. Furthermore, the incidence rate in Alabama in African American women is 10.3/100,000. Thus, the collaboration between investigators at JHU and the Division of Gynecologic Oncology at UAB represents a significant achievement for the Cervical Cancer SPORE Program and significantly improves patient recruitment. The number of cases of invasive carcinoma per annum treated at JHU and UAB, also shown in aggregate (total) and expressed as a percentage of the total number of cases in the USA (American Cancer Society, 2018) are detailed in the table below. In addition, the stage distribution of cervical cancer patients treated at UAB are detailed in the pie chart below. To date, the average age of cervical cancer patients seen was 49, while the racial distribution was: 70% White, 26% Black, and 4% Hispanic/Other.

Cancer Patient Population

YearJHUUABTotal% US cases
2003221471691.38
2004371391761.68
2005211201411.36
2006311441751.80
2007251411661.49
200815911060.96
200930841141.01
201030831130.93
201126781040.85
201235711060.87
201325821070.87
201441881291.01
2015341061441.12
201635971321.02
2017311021331.04